Which has stronger valuation & earnings, SEPN or QTTB?

Q32 Bio has lower revenue, but higher earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Septerna $98.88M 18.37 -$48.88M -$0.54 N/A Q32 Bio $53.74M 8.33 $29.82M $3.00 5.01

Is SEPN or QTTB more profitable?

Q32 Bio has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Q32 Bio's return on equity of 50.17% beat Septerna's return on equity. Company Net Margins Return on Equity Return on Assets Septerna -24.51% -9.57% -6.28% Q32 Bio N/A 50.17% 29.49%

Does the media prefer SEPN or QTTB?

In the previous week, Septerna and Septerna both had 9 articles in the media. Septerna's average media sentiment score of 1.13 beat Q32 Bio's score of 0.44 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Q32 Bio 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, IMCR or QTTB?

Q32 Bio has lower revenue, but higher earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunocore $430.78M 4.38 -$35.51M -$0.37 N/A Q32 Bio $53.74M 8.33 $29.82M $3.00 5.01

Is IMCR or QTTB more profitable?

Q32 Bio has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Q32 Bio's return on equity of 50.17% beat Immunocore's return on equity. Company Net Margins Return on Equity Return on Assets Immunocore -4.20% -4.54% -1.66% Q32 Bio N/A 50.17% 29.49%

Does the media favor IMCR or QTTB?

In the previous week, Q32 Bio had 3 more articles in the media than Immunocore. MarketBeat recorded 9 mentions for Q32 Bio and 6 mentions for Immunocore. Immunocore's average media sentiment score of 1.00 beat Q32 Bio's score of 0.44 indicating that Immunocore is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Q32 Bio 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to QTTB or RXRX?

In the previous week, Recursion Pharmaceuticals had 1 more articles in the media than Q32 Bio. MarketBeat recorded 10 mentions for Recursion Pharmaceuticals and 9 mentions for Q32 Bio. Recursion Pharmaceuticals' average media sentiment score of 0.86 beat Q32 Bio's score of 0.44 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Recursion Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NTLA or QTTB?

In the previous week, Intellia Therapeutics and Intellia Therapeutics both had 9 articles in the media. Intellia Therapeutics' average media sentiment score of 1.12 beat Q32 Bio's score of 0.44 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Q32 Bio 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is DMRA or QTTB more profitable?

Q32 Bio's return on equity of 50.17% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86% Q32 Bio N/A 50.17% 29.49%

Does the media prefer DMRA or QTTB?

In the previous week, Q32 Bio had 5 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 9 mentions for Q32 Bio and 4 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.30 beat Q32 Bio's score of 0.44 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Damora Therapeutics, Inc. Common Stock 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Q32 Bio 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Q32 Bio (QTTB) Competitors

$15.03 -1.12 (-6.93%)

As of 08/28/2026 04:00 PM Eastern

Compare

QTTB vs. SEPN, IMCR, RXRX, NTLA, and DMRA

Should you buy Q32 Bio stock or one of its competitors? Q32 Bio's main competitors and comparable companies include Septerna (SEPN), Immunocore (IMCR), Recursion Pharmaceuticals (RXRX), Intellia Therapeutics (NTLA), and Damora Therapeutics, Inc. Common Stock (DMRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Q32 Bio compare to Septerna?

Septerna (NASDAQ:SEPN) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

31.3% of Q32 Bio shares are owned by institutional investors. 5.8% of Septerna shares are owned by insiders. Comparatively, 34.5% of Q32 Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Septerna and Septerna both had 9 articles in the media. Septerna's average media sentiment score of 1.13 beat Q32 Bio's score of 0.44 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Q32 Bio	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Q32 Bio has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Q32 Bio's return on equity of 50.17% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-24.51%	-9.57%	-6.28%
Q32 Bio	N/A	50.17%	29.49%

Q32 Bio has lower revenue, but higher earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$98.88M	18.37	-$48.88M	-$0.54	N/A
Q32 Bio	$53.74M	8.33	$29.82M	$3.00	5.01

Septerna has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

Septerna currently has a consensus target price of $52.44, suggesting a potential upside of 34.78%. Q32 Bio has a consensus target price of $31.00, suggesting a potential upside of 106.25%. Given Q32 Bio's higher probable upside, analysts clearly believe Q32 Bio is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Q32 Bio beats Septerna on 9 of the 16 factors compared between the two stocks.

How does Q32 Bio compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

In the previous week, Q32 Bio had 3 more articles in the media than Immunocore. MarketBeat recorded 9 mentions for Q32 Bio and 6 mentions for Immunocore. Immunocore's average media sentiment score of 1.00 beat Q32 Bio's score of 0.44 indicating that Immunocore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Q32 Bio	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

84.5% of Immunocore shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 10.1% of Immunocore shares are held by company insiders. Comparatively, 34.5% of Q32 Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Immunocore has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

Immunocore presently has a consensus target price of $56.38, indicating a potential upside of 53.95%. Q32 Bio has a consensus target price of $31.00, indicating a potential upside of 106.25%. Given Q32 Bio's stronger consensus rating and higher possible upside, analysts clearly believe Q32 Bio is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.69
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Q32 Bio has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Q32 Bio's return on equity of 50.17% beat Immunocore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
Q32 Bio	N/A	50.17%	29.49%

Q32 Bio has lower revenue, but higher earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$430.78M	4.38	-$35.51M	-$0.37	N/A
Q32 Bio	$53.74M	8.33	$29.82M	$3.00	5.01

Summary

Q32 Bio beats Immunocore on 11 of the 17 factors compared between the two stocks.

How does Q32 Bio compare to Recursion Pharmaceuticals?

Q32 Bio (NASDAQ:QTTB) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

In the previous week, Recursion Pharmaceuticals had 1 more articles in the media than Q32 Bio. MarketBeat recorded 10 mentions for Recursion Pharmaceuticals and 9 mentions for Q32 Bio. Recursion Pharmaceuticals' average media sentiment score of 0.86 beat Q32 Bio's score of 0.44 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Recursion Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Q32 Bio presently has a consensus price target of $31.00, indicating a potential upside of 106.25%. Recursion Pharmaceuticals has a consensus price target of $8.06, indicating a potential upside of 141.32%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Q32 Bio has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. Q32 Bio's return on equity of 50.17% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	50.17%	29.49%
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 34.5% of Q32 Bio shares are owned by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Q32 Bio has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Q32 Bio has higher earnings, but lower revenue than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	8.33	$29.82M	$3.00	5.01
Recursion Pharmaceuticals	$53.94M	33.15	-$644.76M	-$1.04	N/A

Summary

Q32 Bio beats Recursion Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Q32 Bio compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

In the previous week, Intellia Therapeutics and Intellia Therapeutics both had 9 articles in the media. Intellia Therapeutics' average media sentiment score of 1.12 beat Q32 Bio's score of 0.44 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Q32 Bio	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Intellia Therapeutics has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market.

Q32 Bio has lower revenue, but higher earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$59.51M	30.31	-$412.69M	-$3.36	N/A
Q32 Bio	$53.74M	8.33	$29.82M	$3.00	5.01

Q32 Bio has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. Q32 Bio's return on equity of 50.17% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
Q32 Bio	N/A	50.17%	29.49%

Intellia Therapeutics currently has a consensus price target of $21.15, suggesting a potential upside of 64.35%. Q32 Bio has a consensus price target of $31.00, suggesting a potential upside of 106.25%. Given Q32 Bio's stronger consensus rating and higher possible upside, analysts clearly believe Q32 Bio is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by company insiders. Comparatively, 34.5% of Q32 Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Q32 Bio beats Intellia Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Q32 Bio compare to Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Q32 Bio's return on equity of 50.17% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%
Q32 Bio	N/A	50.17%	29.49%

Q32 Bio has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A
Q32 Bio	$53.74M	8.33	$29.82M	$3.00	5.01

Damora Therapeutics, Inc. Common Stock has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market.

Damora Therapeutics, Inc. Common Stock currently has a consensus price target of $44.00, indicating a potential upside of 51.72%. Q32 Bio has a consensus price target of $31.00, indicating a potential upside of 106.25%. Given Q32 Bio's higher probable upside, analysts clearly believe Q32 Bio is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Q32 Bio had 5 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 9 mentions for Q32 Bio and 4 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.30 beat Q32 Bio's score of 0.44 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Q32 Bio	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Comparatively, 34.5% of Q32 Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Q32 Bio beats Damora Therapeutics, Inc. Common Stock on 10 of the 15 factors compared between the two stocks.

Get Q32 Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QTTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QTTB vs. The Competition

Export

Metric	Q32 Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$447.43M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	5.01	11.62	273.16	25.45
Price / Sales	8.33	1,396.16	640.19	89.89
Price / Cash	9.91	106.39	76.74	53.00
Price / Book	4.22	16.53	12.98	6.14
Net Income	$29.82M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-5.89%	-0.31%	0.13%	-0.80%
1 Month Performance	-3.41%	9.80%	7.08%	4.13%
1 Year Performance	778.95%	55.66%	24.67%	15.17%

Q32 Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QTTB Q32 Bio	3.2478 of 5 stars	$15.03 -6.9%	$31.00 +106.3%	+778.9%	$447.43M	$53.74M	5.01	39	News Coverage Insider Trade
SEPN Septerna	3.3726 of 5 stars	$41.30 +1.9%	$52.44 +27.0%	+221.6%	$1.93B	$45.95M	N/A	N/A	Positive News
IMCR Immunocore	3.6562 of 5 stars	$37.40 +2.2%	$56.38 +50.7%	+13.7%	$1.93B	$400.02M	N/A	320	Positive News
RXRX Recursion Pharmaceuticals	1.884 of 5 stars	$3.56 +9.5%	$8.06 +126.4%	-28.9%	$1.91B	$74.68M	N/A	400	Analyst Upgrade Options Volume
NTLA Intellia Therapeutics	3.0119 of 5 stars	$13.51 +7.6%	$21.15 +56.6%	+13.4%	$1.89B	$67.67M	N/A	600	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QTTB) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Q32 Bio (QTTB) Competitors

QTTB vs. SEPN, IMCR, RXRX, NTLA, and DMRA

How does Q32 Bio compare to Septerna?

Summary

How does Q32 Bio compare to Immunocore?

Summary

How does Q32 Bio compare to Recursion Pharmaceuticals?

Summary

How does Q32 Bio compare to Intellia Therapeutics?

Summary

How does Q32 Bio compare to Damora Therapeutics, Inc. Common Stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB vs. The Competition

Q32 Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Q32 Bio (QTTB) Competitors

QTTB vs. SEPN, IMCR, RXRX, NTLA, and DMRA

How does Q32 Bio compare to Septerna?

Do insiders and institutionals hold more shares of SEPN or QTTB?

Does the media prefer SEPN or QTTB?

Is SEPN or QTTB more profitable?

Which has stronger valuation & earnings, SEPN or QTTB?

Which has more volatility and risk, SEPN or QTTB?

Do analysts prefer SEPN or QTTB?

Summary

How does Q32 Bio compare to Immunocore?

Does the media favor IMCR or QTTB?

Do institutionals & insiders believe in IMCR or QTTB?

Which has more risk and volatility, IMCR or QTTB?

Do analysts recommend IMCR or QTTB?

Is IMCR or QTTB more profitable?

Which has preferable earnings and valuation, IMCR or QTTB?

Summary

How does Q32 Bio compare to Recursion Pharmaceuticals?

Does the media refer more to QTTB or RXRX?

Do analysts recommend QTTB or RXRX?

Is QTTB or RXRX more profitable?

Do insiders and institutionals believe in QTTB or RXRX?

Which has more volatility & risk, QTTB or RXRX?

Which has better valuation & earnings, QTTB or RXRX?

Summary

How does Q32 Bio compare to Intellia Therapeutics?

Does the media prefer NTLA or QTTB?

Which has more risk & volatility, NTLA or QTTB?

Which has stronger valuation and earnings, NTLA or QTTB?

Is NTLA or QTTB more profitable?

Do analysts rate NTLA or QTTB?

Do insiders and institutionals have more ownership in NTLA or QTTB?

Summary

How does Q32 Bio compare to Damora Therapeutics, Inc. Common Stock?

Is DMRA or QTTB more profitable?

Which has higher valuation & earnings, DMRA or QTTB?

Which has more volatility & risk, DMRA or QTTB?

Do analysts rate DMRA or QTTB?

Does the media prefer DMRA or QTTB?

Do insiders & institutionals believe in DMRA or QTTB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB vs. The Competition

Q32 Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools